GREENVILLE, S.C., Jan. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News), the revolutionary heart monitoring company, announced today that it has completed -- for fabrication and ultimate distribution -- its one-of-a-kind cardiac vest that utilizes Signalife’s patented signal amplification technology to allow for precise ECG monitoring of athletes and patients in harsh ambulatory environments.

The cardiac vest, featured on November 30, 2006 in an NBC Today Show’s segment (“Modern Medical Miracles”), has been extensively utilized in testing in the Champ Car World Series open cockpit racing. During these tests, the ECG signals have allowed physicians to evaluate data previously unavailable when captured in the very harsh environment of a race car.

In present cardiac devices, noise and artifact distort ECG recordings in an ambulatory setting. In addition, uncomfortable sticky electrodes are placed on the patient’s torso prior to testing. Skin preparation, which may include shaving hair or skin abrading, is often necessary without the Signalife vest. The Signalife proprietary vest features dry (e.g., quarter-size, metal) electrodes embedded in a cloth fabric which provide better comfort and reduced skin irritation for a large percentage of the clients or patients.

Signalife is aware of no other system that can acquire a similar ECG signal in any ambulatory environment with the use the metal electrodes compatible with Signalife’s cardiac vest.

With these approvals, Signalife will now proceed to submit the vest for accelerated FDA clearance and rapid movement into the marketplace. The completion of the cardiac vest coincides with Signalife’s business plans to “time” its Gold’s Gym initiative with the Company’s other exercise programs. The first Gold’s Gym facility is fully built out, complete with -- among other things -- the cardiac center and other tools to assist the clientele and physicians in screening related to inherent cardiovascular health fitness.

Budimir Drakulic, the Company’s Chief Technology Officer, indicated that he was “very satisfied with the development of the vest and its performance during the Champ Car testing.” Dr. Drakulic said: “Given the difficulty surrounding the recording of electrocardiographic data during car races, Signalife’s R&D team -- and particularly Marko Kostic, the Company’s Champ Car project leader -- deserves praise for the successful development of the cardiac vest and accompanying systems. Download PDF

About Heart Tronics, Inc.
Heart Tronics, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient’s cardiovascular system. Heart Tronics is based in Greenville, South Carolina. For more information visit http://www.Heart Tronics.com.

Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause Heart Tronics’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Heart Tronics’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Heart Tronics’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Heart Tronics’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Heart Tronics’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Heart Tronics’s filings with the Securities and Exchange Commission.